Cognition Therapeutics, Inc. (CGTX)
NASDAQ: CGTX · Real-Time Price · USD
1.730
-0.030 (-1.70%)
At close: Dec 5, 2025, 4:00 PM EST
1.720
-0.010 (-0.58%)
After-hours: Dec 5, 2025, 7:57 PM EST
Cognition Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 10.66 | 12.29 | 13.53 | 13.23 | 10.03 | 4.52 | |
| Research & Development | 34.19 | 41.68 | 37.2 | 30.32 | 18.57 | 12.89 | |
| Operating Expenses | 44.85 | 53.97 | 50.72 | 43.55 | 28.6 | 17.41 | |
| Operating Income | -44.85 | -53.97 | -50.72 | -43.55 | -28.6 | -17.41 | |
| Interest Expense | -0.01 | -0.03 | -0.03 | -0.03 | -0.89 | -1.75 | |
| Currency Exchange Gain (Loss) | -0.2 | -0.2 | - | - | - | - | |
| Other Non Operating Income (Expenses) | 16.88 | 20.22 | 24.96 | 22.18 | 17.33 | 11.45 | |
| EBT Excluding Unusual Items | -28.18 | -33.97 | -25.79 | -21.4 | -12.16 | -7.71 | |
| Other Unusual Items | - | - | - | - | 0.44 | -0.13 | |
| Pretax Income | -27.99 | -33.97 | -25.79 | -21.4 | -11.72 | -7.84 | |
| Net Income | -27.99 | -33.97 | -25.79 | -21.4 | -11.72 | -7.84 | |
| Preferred Dividends & Other Adjustments | - | - | - | - | 4.53 | 4.23 | |
| Net Income to Common | -27.99 | -33.97 | -25.79 | -21.4 | -16.25 | -12.07 | |
| Shares Outstanding (Basic) | 62 | 40 | 30 | 24 | 5 | 1 | |
| Shares Outstanding (Diluted) | 62 | 40 | 30 | 24 | 5 | 1 | |
| Shares Change (YoY) | 70.13% | 32.31% | 27.03% | 355.42% | 921.60% | 8.18% | |
| EPS (Basic) | -0.45 | -0.86 | -0.86 | -0.91 | -3.13 | -23.76 | |
| EPS (Diluted) | -0.46 | -0.86 | -0.86 | -0.91 | -3.13 | -23.76 | |
| Free Cash Flow | -29.53 | -28.48 | -16.17 | -18.7 | -3.66 | -3.44 | |
| Free Cash Flow Per Share | -0.48 | -0.72 | -0.54 | -0.79 | -0.70 | -6.78 | |
| EBITDA | -44.8 | -53.86 | -50.63 | -43.47 | -28.51 | -17.31 | |
| D&A For EBITDA | 0.05 | 0.11 | 0.1 | 0.08 | 0.09 | 0.1 | |
| EBIT | -44.85 | -53.97 | -50.72 | -43.55 | -28.6 | -17.41 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.